Influence of Genetic Polymorphism of Donor on Tacrolimus Concentration in Liver Transplant
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03140462|
Recruitment Status : Not yet recruiting
First Posted : May 4, 2017
Last Update Posted : May 4, 2017
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||400 participants|
|Official Title:||The Influence of ABCB1、CYP3A4、CYP3A5、POR Genetic Polymorphism of Donor on Tacrolimus Blood Concentration in Liver Transplant Patients|
|Estimated Study Start Date :||May 2017|
|Estimated Primary Completion Date :||March 2018|
|Estimated Study Completion Date :||March 2019|
liver transplant patients and donors
To study clinical and genetic factors on tacrolimus dose normalized trough concentration.
- Dose normalized trough concentration of tacrolimus in liver transplant patients within the first 6 months post-transplantation [ Time Frame: Within the first 6 months post-transplantation ]Analyse the effect of the donor's genetic polymorphism to dose normalized trough concentration of tacrolimus in liver transplant patients. Trough level of tacrolimus was adjusted by liver recipient's body weight.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03140462
|Contact: Fe-Lin Lin Wu||+886-2-3366 email@example.com|
|National Taiwan University Hospital||Not yet recruiting|
|Contact: Rey-Heng Hu|
|Principal Investigator:||Rey-Heng Hu||National Taiwan University Hospital|